View the poster here

The new EU Pharmaceutical legislation sets out criteria for manufacturers that must be met before maximum market exclusivity can be gained. The implications of the proposed reforms in terms of launch timelines, assessment requirements and equitable access to medicines (in particular ATMPs) across Member States is an area of high uncertainty, which has been investigated further through this research.

Using the Lightning Insights platform to survey payers and HTA representatives, our research programme explored stakeholder perceptions of the proposed legislation, with a focus on implementation in member states where patient access to new medicines is currently more limited; Croatia, Greece, Hungary, Poland, Portugal, Romania and Slovakia.

To learn more about this recent research and how Lightning Insights was used to inform this poster, contact our expert team.

Article published 13 November 2023.